reports
- John Savin PhD
- Robin Davison
Tiziana Moving forward in MS and AD
Tiziana is close to being able to start the important phase IIa study with its lead product, intranasal foralumab, in non-active secondary progressive multiple sclerosis (SPMS) and is well advanced in its plan to initiate a separate study in Alzheimer's disease (AD).Within the next two months, Tizi
- John Savin PhD
- Robin Davison
Expansion into new clinical indications
Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19. These could represent the second and third clinical indications for
- John Savin PhD
- Robin Davison
2023 clinical outlook
Tiziana's lead product is foralumab, a fully human antibody. This is administered to mucosal surfaces in the nose (intranasal) to boost regulatory T-cell (T-reg) responses with the aim of controlling autoimmune disease progression in central nervous system (CNS) indications like multiple sclerosis
- John Savin PhD
- Robin Davison
Extending into Alzheimers
Tiziana Life Sciences has announced that it plans to take foralumab, its fully human anti-CD3 monoclonal, into a clinical study in Alzheimer's disease. The Company obtained good initial results from an animal model. Further preclinical work will be needed before an Investigational New Drug Applicat
- John Savin PhD
- Robin Davison
Second SPMS patient shows response, trial expands
Tiziana Life Sciences has reported that positive imaging and functional results have been seen in the second patient with secondary progressive multiple sclerosis (SPMS) enrolled in its expanded access study of intra-nasally delivered foralumab. The data points were measured after three months of t
- John Savin PhD
- Robin Davison
Multiple Sclerosis single study
Tiziana Life Sciences uses its delivery technology to administer its fully human therapeutic anti-CD3 antibody, foralumab, to mucosal surfaces in the nose or gut; antibodies are usually injected or infused giving Tiziana a novel market position. Foralumab potentially modulates the immune system, so
- John Savin PhD
- Robin Davison
2022 update: US listing and fresh data emerging
Tiziana Life Sciences delivers its fully human therapeutic antibody, foralumab, to mucosal surfaces in the nose or gut aiming to modulate various autoimmune diseases. A key project is running in Multiple Sclerosis (MS) with nasal foralumab. There is positive progress in the individual patient expan
- John Savin PhD
- Julian Hofmann
- Robin Davison
Controlling disease using a safe, nasal and oral antibody
Tiziana Life Sciences delivers its fully human therapeutic antibody, foralumab, to the gut or nose mucosal surfaces aiming to modulate the immune response. This might help to control various autoimmune diseases such as Crohn’s and Multiple Sclerosis (MS).Foralumab has also been clinically tested wi
- John Savin PhD
- Robin Davison
New use for foralumab in CAR T-cell therapy
Tiziana has a fully human therapeutic monoclonal antibody, foralumab, currently being developed for nasal, inhaled and oral delivery to treat autoimmune disease and COVID-19; it is the only fully human anti-CD3 monoclonal. Precision Biosciences, Tiziana’s new US partner, is developing “off-the-shel
- Emma Ulker
Tiziana Life Sciences: Advancing the therapeutic pipeline
Tiziana (LON:TILS, NASDAQ:TLSA) is advancing its lead immunotherapy Foralumab, a fully-human anti-CD3 monoclonal antibody (mAb) being developed for oral and nasal routes of administration, providing novel approaches in treating severe inflammatory and autoimmune disease. Top-line data from a recent
- Emma Ulker
Tiziana Life Sciences: Expanding the pipeline, unlocking value
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has expanded the range of indications — which include severe inflammatory and autoimmune diseases — of its lead therapy fully human anti-CD3 monoclonal antibody Foralumab, signing a new collaboration in Brazil to develop the nasal formulation of For
- Emma Ulker
Tiziana Life Sciences: Advancing at speed
Tiziana (TILS), also listed on NASDAQ (Symbol TLSA), is driving forwards the clinical development plan for its fully-human mAb TZLS-501 for treating COVID-19 respiratory symptoms and has set out the detail of its clinical plan being executed by a group of specialist contract research organisations
- Emma Ulker
Tiziana Life Sciences: Transformational potential
Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by TILS
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP M...
Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19 This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 NEW YORK and LONDON, June 29, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company deve...
Tiziana Granted First-Ever Patent on a Transformational Technology for...
Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapiesTransformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 19, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology ...
Tiziana Life Sciences announces that its Scientific Advisory Board Cha...
Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 04, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Chairman of the Company’s Scientific Advisory Board, Dr. Howard Wein...
Tiziana Life Sciences announces presentation of StemPrintER, a superio...
Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patientsSPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for onco...
Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Ge...
Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed Company NEW YORK and LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER and SPARE (together "StemPrintER") genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and list...
Tiziana Lifesciences Announces Online Publication of Two Abstracts at ...
Tiziana Lifesciences Announces Online Publication of Two Abstracts at the American Society of Clinical Oncology (ASCO) Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the on...
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Sup...
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, May 14, 2020 (GLOBE NEWSWIRE) -...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.